Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: Retrospective analysis of data from the CREDOS study

Journal of Clinical Psychiatry

Volumn 73, Issue 12, 2012, Pages 1555-1562

  Son, Sang Joon ^a,b   Lee, Kang Soo ^c   Lee, Yunhwan ^a   Baek, Jong Hwan ^a   Choi, Seong Hye ^d   Na, Duk L ^e   Seo, Sang Won ^e   Oh, Byoung Hoon ^f   Hong, Chang Hyung ^a,b  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University Medical Center   (South Korea)

^c CHA University   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALLELE; ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-IV; FEMALE; FUNCTION TEST; GENOTYPE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SOUTH KOREA; VERBAL MEMORY; WHITE MATTER LESION;

EID: 84871841863     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07702     Document Type: Article

References (53)

1. Verdelho A, Madureira S, Moleiro C, et al; on behalf of the LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology. 2010;75(2):160-167. doi:10.1212/WNL.0b013e3181e7ca05 PubMed
2. Carmichael O, Schwarz C, Drucker D, et al Alzheimer's Disease Neuroimaging Initiative. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol. 2010;67(11):1370-1378. doi:10.101/archneurol.2010.284 PubMed
3. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord. 1998;9(suppl 1):6-12. doi:10.159/05183 PubMed (Pubitemid 28325636)
4. Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29(6):1177-1181. doi:10.161/01.STR.29.6.17 PubMed (Pubitemid 28265474)
5. de Leeuw FE, Richard F, de Groot JC, et al. Interaction between hypertension, APOE, and cerebral white matter lesions. Stroke. 2004;35(5):1057-1060. doi:10.161/01.STR.0125859.71051.83 PubMed (Pubitemid 38543516)
6. DeCarli C, Reed T, Miller BL, et al. Impact of apolipoprotein E ε4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke. 1999;30(8):1548-1553. doi:10.161/01.STR.30.8.1548 PubMed (Pubitemid 29379601)
7. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(6):2892-2897. doi:10.1073/pnas.0504797 PubMed (Pubitemid 30159268)
8. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622-630. doi:10.126/science. 3283935 PubMed
9. Szolnoki Z. Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromolecular Med. 2007;9(1):21-33. doi:10.1385/NM:9:1:21 PubMed
10. Godin O, Tzourio C, Maillard P, et al. Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke. 2009;40(10):3186- 3190. doi:10.161/STROKEAHA.109.5839 PubMed
11. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology. 1999;53(6):1308-1311. doi:10.1212/WNL.53.6.1308 PubMed (Pubitemid 29480092)
12. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of â-amyloid protein. N Engl J Med. 1995;333(19):1242-1247. doi:10.1056/NEJM19510931902 PubMed
13. Barber R, Gholkar A, Scheltens P, et al. Apolipoprotein E ε4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol. 1999;56(8):961-965. PubMed (Pubitemid 29374813)
14. Hirono N, Yasuda M, Tanimukai S, et al. Effect of the apolipoprotein E ε4 allele on white matter hyperintensities in dementia. Stroke. 2000;31(6):1263-1268. doi:10.161/01.STR.31.6.1263 PubMed (Pubitemid 30351243)
15. Wolk DA, Dickerson BC; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010;107(22):10256-10261. doi:10.1073/pnas.101412107 PubMed
16. Au R, Massaro JM, Wolf PA, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006;63(2):246-250. doi:10.101/archneur.63.2.246 PubMed (Pubitemid 43261736)
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
18. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939 PubMed (Pubitemid 14076461)
19. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308. doi:10.101/archneur.56.3.303 PubMed (Pubitemid 29120227)
20. Hong YJ, Yoon B, Shim YS, et al. APOE ε4 allele status in Korean dementia patients with severe white matter hyperintensities. J Alzheimers Dis. 2011;24(3):519-524. PubMed
21. Kang Y, Na DL, Hanhn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc. 1997;15:300-307.
22. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. doi:10.1212/WNL.43.1.2412-a PubMed (Pubitemid 23346995)
23. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: Haworth Press; 1986:165-173. (Pubitemid 17221439)
24. Kang Y, Na DL. Seoul Neuropsychological Screening Battery (SNSB). Seoul, Republic of Korea: Human Brain Research and Consulting Co; 2003.
25. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-356. PubMed (Pubitemid 17104996)
26. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114(1):7-12. doi:10.1016/02-510X(93)9041-V PubMed
27. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337(8750):1158-1159. doi:10.1016/0140-6736(91)92823-K PubMed
28. Lesser IM, Boone KB, Mehringer CM, et al. Cognition and white matter hyperintensities in older depressed patients. Am J Psychiatry. 1996;153(10):1280-1287. PubMed (Pubitemid 26334200)
29. Knopman DS. Dementia and cerebrovascular disease. Mayo Clin Proc. 2006;81(2):223-230. doi:10.4065/81.2.23 PubMed (Pubitemid 43205777)
30. Hedden T, Van Dijk KR, Shire EH, et al. Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex. 2012;22(5):1038-1051. PubMed
31. DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology. 1995;45(11):2077-2084. doi:10.1212/WNL.45.1.207 PubMed
32. Erixon-Lindroth N, Farde L, Wahlin TB, et al. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 2005;138(1):1-12. doi:10.1016/j.pscychresns.204.09.05 PubMed (Pubitemid 40228957)
33. Murray ME, Senjem ML, Petersen RC, et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol. 2010;67(11):1379-1385. doi:10.101/archneurol.2010.280 PubMed
34. Marra C, Bizzarro A, Daniele A, et al. Apolipoprotein E ε4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement Geriatr Cogn Disord. 2004;18(2):125-131. doi:10.159/079191 PubMed (Pubitemid 39140361)
35. van der Vlies AE, Pijnenburg YA, Koene T, et al. Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord. 2007;24(2):98-103. doi:10.159/010467 PubMed (Pubitemid 47094068)
36. Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology. 1996;46(2):413-419. doi:10.1212/WNL.46.2.413 PubMed (Pubitemid 26081323)
37. Smith GE, Bohac DL, Waring SC, et al. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology. 1998;50(2):355-362. doi:10.1212/WNL.50.2. 35 PubMed
38. Hashimoto M, Yasuda M, Tanimukai S, et al. Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology. 2001;57(8):1461-1466. doi:10.1212/WNL.57.8.1461 PubMed (Pubitemid 32995729)
39. Geroldi C, Pihlajamäki M, Laakso MP, et al. APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53(8):1825-1832. doi:10.1212/WNL.53.8.1825 PubMed (Pubitemid 29530361)
40. Agosta F, Vossel KA, Miller BL, et al. Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A. 2009;106(6):2018-2022. doi:10.1073/pnas.0812697106 PubMed
41. Lehtovirta M, Laakso MP, Soininen H, et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience. 1995;67(1):65-72. doi:10.1016/0306-452(95)014-A PubMed
42. Juottonen K, Lehtovirta M, Helisalmi S, et al. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry. 1998;65(3):322-327. doi:10.136/jnp.65.3.32 PubMed (Pubitemid 28408245)
43. Caselli RJ, Walker D, Sue L, et al. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett. 2010;473(3):168-171. doi:10.1016/j.neulet.2010.02.016 PubMed
44. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825. doi:10.1073/pnas.090345106 PubMed
45. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62(3):229-234. doi:10.102/ana.2164 PubMed (Pubitemid 47525398)
46. Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol. 2010;68(4):545-548. doi:10.102/ana.209 PubMed
47. Gurol ME, Irizarry MC, Smith EE, et al. Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66(1):23-29. doi:10.1212/01.wnl.0191403.95453.6a PubMed (Pubitemid 43739586)
48. Caselli RJ, Dueck AC, Locke DE, et al. Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers. Neurology. 2011;76(16):1383-1388. doi:10.1212/WNL.0b013e3182167147 PubMed
49. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178-188. doi:10.1016/j.neuron.209.07.03 PubMed
50. Weintraub S, Mesulam M. With or without FUS, it is the anatomy that dictates the dementia phenotype. Brain. 2009;132(11):2906-2908. doi:10.1093/brain/awp286 PubMed
51. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23-30. PubMed (Pubitemid 30479402)
52. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683-1689. doi:10.1212/WNL.43.9.1683 PubMed (Pubitemid 23307935)
53. Lemmens R, Görner A, Schrooten M, et al. Association of apolipoprotein E ε2 with white matter disease but not with microbleeds. Stroke. 2007;38(4):1185-1188. doi:10.161/01.STR.0259816.31370.4 PubMed (Pubitemid 351664274)